These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
76 related articles for article (PubMed ID: 7871286)
41. Progesterone binding cyst protein in hormone receptor positive breast cancer; a predictive factor for effect of adjuvant tamoxifen treatment. Søreide JA; Kolnes J; Skarstein A; Aas T; Kvinnsland S Anticancer Res; 1994; 14(5B):2105-8. PubMed ID: 7840507 [TBL] [Abstract][Full Text] [Related]
42. Breast epithelial antigens in the circulation of breast cancer patients. Ceriani RL; Rosenbaum EH Immunol Ser; 1990; 53():223-41. PubMed ID: 2100557 [No Abstract] [Full Text] [Related]
43. Structural study of GCDFP-15/gp17 in disease versus physiological conditions using a proteomic approach. Caputo E; Camarca A; Moharram R; Tornatore P; Thatcher B; Guardiola J; Martin BM Biochemistry; 2003 May; 42(20):6169-78. PubMed ID: 12755619 [TBL] [Abstract][Full Text] [Related]
44. Antibody sources. Mazoujian G Am J Surg Pathol; 1991 Dec; 15(12):1207-8. PubMed ID: 1660678 [No Abstract] [Full Text] [Related]
45. Clinical value of tumour-associated antigens. Neville AM J Clin Pathol Suppl (R Coll Pathol); 1974; 7():119-26. PubMed ID: 4208587 [No Abstract] [Full Text] [Related]
46. Non-human primate (baboon) anti-gross cystic disease fluid protein-15 antibody infusion in four women with metastatic breast carcinoma. Estabrook A; Kister SJ; Hardy MA; Grossbard L; Oster MW; Davis S; Mazoujian G; Haagensen DE Cancer Immunol Immunother; 1986; 23(2):143-7. PubMed ID: 3490912 [TBL] [Abstract][Full Text] [Related]
47. Immunohistochemical stains for breast cancer. Roche PC Mayo Clin Proc; 1994 Jan; 69(1):57-8. PubMed ID: 8271853 [No Abstract] [Full Text] [Related]
49. Identification of a tumour antigen. Carnegie PR; Caspary EA; Field EJ Biochem J; 1972 Feb; 126(3):5P-6P. PubMed ID: 5075270 [No Abstract] [Full Text] [Related]
50. [Breast carcinoma metastatic to meningioma: review of the literature and description of 2 new cases]. Fornelli A; Bacci A; Collina G; Eusebi V Pathologica; 1995 Oct; 87(5):506-12. PubMed ID: 8868176 [TBL] [Abstract][Full Text] [Related]
51. [Is there value in determining tumor markers in senology?]. Van Cauwenberge JR; Collette J; Franchimont P Rev Med Liege; 1995 Jan; 50(1):41-5. PubMed ID: 7871286 [No Abstract] [Full Text] [Related]
52. Monitoring of hormonal therapy in patients with metastatic breast carcinoma by plasma marker protein profiles. Haagensen DE; Dilley WG; Cox CE; Giannola JE; Wells SA Surg Forum; 1978; 29():162-4. PubMed ID: 401123 [TBL] [Abstract][Full Text] [Related]
53. Immunoperoxidase staining for tumor markers in patients with carcinoma of the breast. Cox CE; Haagensen DE; Dilley WG; Wells SA Surg Forum; 1978; 29():160-2. PubMed ID: 401405 [No Abstract] [Full Text] [Related]
54. Tumor markers for breast carcinoma. Haagensen DE Clin Lab Med; 1982 Sep; 2(3):543-65. PubMed ID: 6754225 [No Abstract] [Full Text] [Related]
55. Breast cancer metastatic to the eyelids. Claessens N; Rakic L; Arrese JE; Pierard GE Eur J Dermatol; 2000 Aug; 10(6):473-4. PubMed ID: 10980473 [TBL] [Abstract][Full Text] [Related]